Understanding the human body is a team effort. That's where the Yachtel group comes in.

Researchers at Yachtolt have been delving into the secrets of probiotics for 90 years. Yacold also

partners with nature portfolio to advance gut microbiome science through the global grants for

gut health, an investigator-led research program. To learn more about Yachtold, visit yacolt.co.com.

That's Y-A-K-U-L-T dot-C-O-J-P. When it comes to a guide for your gut, count on Yacolt.

Hey, science nerds, happy Monday. It's Kelso Harper, multimedia editor here at Scientific American. I am once again filling in

for Rachel Feldman while she's out because, well, the news moves fast and microphones are a pain

to drag around on vacation. Rachel will be back in your feed later this week to talk about

the surprisingly mysterious science of tattoos and back to her usual Monday routine next week.

But for now, it's time to catch up on some news.

Okay, let's jump in.

Last Tuesday, the Centers for Disease Control and Prevention endorsed what it's calling

the first new STI prevention tool in decades.

It's an antibiotic called doxycycline post-exposure prophylaxis, or doxypep for short,

and it's a sort of morning after pill for sexually transmitted infections or STIs.

Research done on men who have sex with men, as well as on transgender women, indicates that

taking a single dose of the antibiotic within three days of unprotected sex can help prevent bacterial

STIs, namely syphilis, chlamydia, and gonorrhea.

But the CDC says more research will be needed before it can

recommend doxypep for other groups. This is a tool we definitely need, though, because while

the number of gonorrhea cases in the U.S. finally appear to be dropping after rising for more

than a decade, chlamydia cases have plateaued at best, and syphilis is still on the rise,

...